Restricted Cash

The Company designated $17.5 million as collateral for a security bond posted in the litigation against Amphastar and International Medical Systems, Ltd., a wholly owned subsidiary of Amphastar Pharmaceuticals, Inc. Additional information regarding the litigation is discussed within Note 14, Commitments and Contingencies. The $17.5 million is held in an escrow account by Hanover Insurance. The Company classified this restricted cash as long-term as the timing of a final decision in the Enoxaparin Sodium Injection patent litigation is not known.

The following table summarizes the amounts designated as collateral for letters of credit related to the lease of office and laboratory space in Cambridge, Massachusetts (collateral amounts are presented in thousands).



Property Location	Approximate Square Footage	Lease Expiration Date	Letter of Credit Amount		Balance Sheet Classification
675 West Kendall Street	78,500	4/30/2018	$	2,412	Current Asset
320 Bent Street	105,000	2/28/2027	748		Non-Current Asset
301 Binney Street, Fifth Floor	80,000	6/29/2025	1,101		Non-Current Asset
301 Binney Street, Fourth Floor	52,000	3/31/2028	1,271		Non-Current Asset
Total			$	5,532